JP5543329B2 - ベルノニア属抽出物の使用 - Google Patents
ベルノニア属抽出物の使用 Download PDFInfo
- Publication number
- JP5543329B2 JP5543329B2 JP2010503376A JP2010503376A JP5543329B2 JP 5543329 B2 JP5543329 B2 JP 5543329B2 JP 2010503376 A JP2010503376 A JP 2010503376A JP 2010503376 A JP2010503376 A JP 2010503376A JP 5543329 B2 JP5543329 B2 JP 5543329B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- synthesis
- extraction
- vernonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims description 45
- 241000736800 Vernonia Species 0.000 title claims 3
- 239000000203 mixture Substances 0.000 claims description 32
- 210000003491 skin Anatomy 0.000 claims description 26
- 230000002500 effect on skin Effects 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 claims description 8
- 108010066321 Keratin-14 Proteins 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 210000004207 dermis Anatomy 0.000 claims description 8
- 210000002615 epidermis Anatomy 0.000 claims description 8
- 239000000419 plant extract Substances 0.000 claims description 7
- 239000002798 polar solvent Substances 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 4
- 238000005728 strengthening Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 240000001689 Cyanthillium cinereum Species 0.000 description 24
- 239000000126 substance Substances 0.000 description 13
- 241000353849 Appendicula Species 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 5
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940074393 chlorogenic acid Drugs 0.000 description 4
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 4
- 235000001368 chlorogenic acid Nutrition 0.000 description 4
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000001215 fluorescent labelling Methods 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- -1 serums Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 201000000744 recessive dystrophic epidermolysis bullosa Diseases 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DRBARRGCABOUIE-UHFFFAOYSA-N 2,3-dihydroxy-3-phenylprop-2-enoic acid Chemical class OC(=O)C(O)=C(O)C1=CC=CC=C1 DRBARRGCABOUIE-UHFFFAOYSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 description 1
- MVCIFQBXXSMTQD-UHFFFAOYSA-N 3,5-dicaffeoylquinic acid Natural products Cc1ccc(C=CC(=O)OC2CC(O)(CC(OC(=O)C=Cc3ccc(O)c(O)c3)C2O)C(=O)O)cc1C MVCIFQBXXSMTQD-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000301 hemidesmosome Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000000485 pigmenting effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008275 solid aerosol Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Description
DEJは、第一に、表皮の支持体である:基底のケラチノサイトは、ヘミデスモソームおよび透明板でケラチノサイトアクチン細胞骨格を固定するサイトケラチン14タンパク質により、透明板(DEJの上部)に連結する。
DEJは、また、皮膚を構造化し、緻密板のコラーゲンIVの高い含有量が機械的耐性に関係し、典型的な表皮突稜パターンが表皮と真皮の間の交換表面を増やす。
DEJは、例えば、網状層(これは、また、真皮網状層とも呼ばれ、実際に真皮乳頭層の上部であり、高い細胞および血管の含有量を特徴とする)での溶質の供給および濾過により、皮膚の情報交換に関わる。
DEJは、特に、ラミニンV糖タンパク質(透明板および緻密板に分布する接着フィラメント)またはコラーゲンVII(緻密板に入り込み、真皮乳頭層を通って伸びる、曲がった原線維)により、表皮と真皮の間の皮膚の接着に必須である。
本発明によるベルノニア属抽出物は、ベルノニア・アッペンディキュラタ、ベルノニア・チャペリエリ(chapelieri)、ベルノニア・ジベルシフォリア(diversifolia)、ベルノニア・スブルテア、ベルノニア・トリネルビス(trinervis)、ベルノニア・トリコデルマ(trichoderma)、ベルノニア・ペクトラリス(pectoralis)、ベルノニア・モキノイデス(moquinoides)およびベルノニア・エリオフィラ(eryophylla)を含むがこれらに限定されない、マダガスカル原産のベルノニア科の植物の抽出物である。好ましいのは、ベルノニア・アッペンディキュラタである。
抽出は、標準的抽出方法により行うことができる。好ましくは、抽出に適用できる極性溶媒を用いて抽出を実施する。葉を最初に極性溶媒で、場合により数回、抽出する。次いで、得られる溶液を混合し、非極性溶媒、例えばヘプタンで抽出し、蝋、精油、色素および非極性分子の殆どを除去する。相分離後、植物性抽出物含有量を、グリセリン−水配合物1:1中、最低10重量%の乾燥抽出物に調節するために、グリセリンを水性溶液に添加する。
好ましいのは、本発明による抽出物の溶液、好ましくは水をベースとする溶液を、全組成物の重量の0.1%ないし10%、好ましくは1%ないし7%の量で含有する組成物である。
実施例1:ベルノニア・アッペンディキュラタ抽出物
乾燥させたベルノニア・アッペンディキュラタの葉を、最初にヘプタンで抽出し、その後エタノールで浸出する。次いで、脂肪の除去を、ヘプタンを用いる液体−液体抽出により達成する。水相への濃縮の後、グリセリンを添加し、水−グリセリン配合物中の10%w/vの植物性抽出物に溶液を調節する。その結果、最終生成物は液体形態である。
組成物をHPLCにより試験でき、(乾燥)植物性抽出物の典型的な組成物は、全抽出物の重量の5%を超えるクロロゲン酸およびイソクロロゲン酸を含有する。
このエクスビボ実験では、腹部形成手術からの生検を使用する。それらを特別な生存用移植片培地:BEM(BIO-EC's Explants Medium)中で培養する。
モウリー(Mowry)染色法(アルシアンブルー染色)によりGAGの特異的免疫染色を実施し、真皮乳頭層中および真皮表皮接合部(DEJ)に沿って存在するGAGを、桃色−すみれ色の染色により可視化する。
全ての生検について、真皮乳頭層中に存在する酸GAGの活性化はない。非処置皮膚条片に関して、中性GAGは、不規則な薄いバンドの中程度の染色で、DEJに沿って存在する。ベルノニア・アッペンディキュラタ抽出物で処置した移植片について、中性GAGは、DEJに沿って明確に標識され、規則的な薄いバンドを形成する(図1)。標識の増幅は、ベルノニア・アッペンディキュラタ抽出物による処置が、真皮のGAG含有量を高めることを示す。
モノクローナル抗体の抗−ケラチン14(Progen ref RCK107)によりサイトケラチン14の特異的免疫標識を実施し、FITCにより解明する。次いで、細胞核をヨウ化プロポジウム(propodium)で染色する。次いで、真皮表皮接合部領域で蛍光標識によりケラチン14を観察できる。
非処置皮膚条片に関して、基底ケラチノサイト層で標識は明確であり、おおよそ規則的である。それは第2細胞層では薄い。ベルノニア・アッペンディキュラタ抽出物で処置した移植片について、標識は基底ケラチノサイト層で非常に明確かつ規則的であり、第2細胞層で中程度である(図2)。
ベルノニア・アッペンディキュラタ抽出物による処置は、表皮におけるサイトケラチン14放出の上方調節を助ける。
モノクローナル抗体の抗ラミニンV(Santa Cruz ref sc 13587)によりラミニンVの特異的免疫標識を実施し、FITCにより解明する。次いで、細胞核をヨウ化プロポジウムで染色する。次いで、真皮表皮接合部領域で蛍光標識によりラミニンVを観察できる。
標識は、非処置生検の細胞膜でかなり明確であり、おおよそ規則的であるが、ベルノニア・アッペンディキュラタ抽出物による処置後に、非常に明確かつ非常に規則的である(図3)。
ベルノニア・アッペンディキュラタ抽出物による処置は、ラミニンV含有量の上方調節を助ける。
このエクスビボ実験では、腹部形成手術からの生検を使用する。それらを特別な生存用移植片培地:BEM(BIO-EC's Explants Medium)中で培養する。
形態学的分析のために、移植片を脱水およびパラフィン包埋の後にブアン固定液で固定する。次いで、それらを切片にし、マッソン・トリコームにより染色する。
冷凍したクライオスタット切断組織に、モノクローナル抗体の抗コラーゲンIV(SBA)によりコラーゲンIVの特異的免疫標識を実施し、FITCにより解明する。次いで、細胞核をヨウ化プロポジウムで染色する。次いで、真皮表皮接合部領域および上部の真皮乳頭層で蛍光標識によりコラーゲンIVを観察できる。
画像のデジタル化の後に画像分析を実施し、染色に占められる表面を評価する。コラーゲンIVにより占められる表面の百分率は、ベルノニア・アッペンディキュラタ抽出物で処置した生検について、非処置の切除された皮膚または賦形剤で処置されたものよりも大きい:賦形剤に対して+23.4%、非処置に対して+24.8%。これらの値は、レチノール製剤で得られる結果に匹敵する。
Claims (9)
- 抗老化効果を有することにより、皮膚を緻密化および堅固化することにより、および/または、表皮真皮接合部を強化することにより皮膚の状態を改善するための組成物を製造するための、極性溶媒による抽出により得られるベルノニア・アッペンディキュラタの葉の抽出物の使用。
- ラミニンV合成の活性化、コラーゲンIV合成の活性化、サイトケラチン14合成の活性化、および/または、グルコサミノグリカン合成の活性化により、皮膚の状態を改善するための、請求項1に記載の使用。
- 皮膚の輝度の改善、表皮真皮接合部の接着の改善、皮膚の構造化の改善、表皮と真皮の間の機能的接合面の保護および/または皮膚の水分含有量の改善のための、請求項1ないし請求項2のいずれかに記載の使用。
- 抽出物が、少なくとも1種のさらなる活性物質または植物抽出物と組み合わされる、請求項1ないし請求項3のいずれかに記載の使用。
- 抽出物が、皮膚科的または美容的な使用に通常用いられる少なくとも1種のさらなる活性物質または植物抽出物と組み合わされる、請求項4に記載の使用。
- 局所投与のための、極性溶媒による抽出により得られるベルノニア・アッペンディキュラタの葉の抽出物を含有する皮膚科用または美容用組成物。
- 抽出物の溶液を、全組成物の重量の0.1%ないし10%の量で有する、請求項6に記載の皮膚科用または美容用組成物。
- 抽出物が、極性溶媒によるベルノニア・アッペンディキュラタの葉の抽出と、それに続く脂質除去のための非極性溶媒による抽出により得られるものである、請求項6または請求項7に記載の皮膚科用または美容用組成物。
- 極性溶媒がアルコールまたは水とアルコールの混合物である、請求項8に記載の皮膚科用または美容用組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07290472.5 | 2007-04-17 | ||
EP07290472 | 2007-04-17 | ||
PCT/EP2008/002689 WO2008125237A2 (en) | 2007-04-17 | 2008-04-04 | Use of vernonia appendiculata extract for improving the skin status |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010524868A JP2010524868A (ja) | 2010-07-22 |
JP5543329B2 true JP5543329B2 (ja) | 2014-07-09 |
Family
ID=39864406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010503376A Active JP5543329B2 (ja) | 2007-04-17 | 2008-04-04 | ベルノニア属抽出物の使用 |
Country Status (9)
Country | Link |
---|---|
US (2) | US9339521B2 (ja) |
EP (1) | EP2150262B1 (ja) |
JP (1) | JP5543329B2 (ja) |
KR (1) | KR20090130066A (ja) |
CA (1) | CA2683731A1 (ja) |
CL (1) | CL2008001066A1 (ja) |
ES (1) | ES2603877T3 (ja) |
PE (1) | PE20090232A1 (ja) |
WO (1) | WO2008125237A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2649987A1 (en) * | 2012-04-11 | 2013-10-16 | Bayer Consumer Care AG | Embelia concinna extract comprising flavonoids in cosmetic and pharmaceutical compositions |
US20150359732A1 (en) * | 2013-03-13 | 2015-12-17 | Avon Products, Inc. | Vernonia cinerea extracts and methods of use |
US10335444B2 (en) | 2014-06-13 | 2019-07-02 | Pawan Kumar Goel | Method for extracting high content of chlorogenic acids from green coffee beans |
CN112370387B (zh) * | 2020-11-03 | 2022-01-14 | 珀莱雅化妆品股份有限公司 | 一种具有头皮护理功效的植物双向发酵物的制备方法及其应用 |
KR20230076874A (ko) * | 2021-11-22 | 2023-06-01 | 바이오스펙트럼 주식회사 | 이소클로로겐산 또는 이의 염을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1060649C (zh) | 1992-12-12 | 2001-01-17 | 杜文超 | 一种治疗白癜风药物 |
CN1049146C (zh) | 1995-07-21 | 2000-02-09 | 王琨宣 | 治疗白癜风的复方驱虫斑鸠菊片 |
GB9920393D0 (en) * | 1999-08-27 | 1999-11-03 | Medix Scient Uk Limited | Plant extract mixtures and their uses |
FR2804319B1 (fr) * | 2000-01-28 | 2002-10-25 | Clarins Lab | Composition cosmetique amincissante comprenant en tant qu'agent actif un extrait de plante contenant de l'anp |
JP4880816B2 (ja) * | 2000-12-15 | 2012-02-22 | 株式会社ヤクルト本社 | 皮膚老化防止剤 |
US20020127256A1 (en) * | 2001-03-01 | 2002-09-12 | Howard Murad | Compositions and methods for treating dermatological disorders |
GB0600134D0 (en) * | 2006-01-05 | 2006-02-15 | Vernique Biotech Ltd | Use of epoxidised molecules |
CA2647356A1 (en) * | 2006-03-31 | 2007-10-11 | Panacea Biotec Ltd. | Compositions for hair loss disorders comprising extracts from the plant vernonia sp. |
FR2900820B1 (fr) * | 2006-05-10 | 2008-10-03 | Dermatologiques D Uriage Lab | Utilisation d'extraits de plantes a des fins cosmetiques ou dermatologiques et les compositions contenant ces extraits |
-
2008
- 2008-04-04 ES ES08735021.1T patent/ES2603877T3/es active Active
- 2008-04-04 EP EP08735021.1A patent/EP2150262B1/en active Active
- 2008-04-04 CA CA002683731A patent/CA2683731A1/en not_active Abandoned
- 2008-04-04 WO PCT/EP2008/002689 patent/WO2008125237A2/en active Application Filing
- 2008-04-04 JP JP2010503376A patent/JP5543329B2/ja active Active
- 2008-04-04 KR KR1020097021653A patent/KR20090130066A/ko not_active Application Discontinuation
- 2008-04-15 PE PE2008000651A patent/PE20090232A1/es not_active Application Discontinuation
- 2008-04-15 CL CL200801066A patent/CL2008001066A1/es unknown
-
2009
- 2009-10-16 US US12/589,026 patent/US9339521B2/en active Active
-
2016
- 2016-05-13 US US15/154,242 patent/US20170007654A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110097429A1 (en) | 2011-04-28 |
EP2150262B1 (en) | 2016-08-31 |
US9339521B2 (en) | 2016-05-17 |
PE20090232A1 (es) | 2009-04-01 |
WO2008125237A2 (en) | 2008-10-23 |
KR20090130066A (ko) | 2009-12-17 |
WO2008125237A3 (en) | 2009-10-01 |
CA2683731A1 (en) | 2008-10-23 |
US20170007654A1 (en) | 2017-01-12 |
JP2010524868A (ja) | 2010-07-22 |
ES2603877T3 (es) | 2017-03-01 |
CL2008001066A1 (es) | 2008-10-24 |
EP2150262A2 (en) | 2010-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102108916B1 (ko) | 피부 생기 부여 및 활력 증대를 위한 식물세포 컴플렉스 배양물 또는 그 추출물을 함유하는 피부개선용 화장료 조성물 | |
JP6387219B2 (ja) | タンゲレチン及びegcgを含有する皮膚外用剤組成物 | |
TW201206494A (en) | Use of Tiliacora triandra in cosmetics and compositions thereof | |
US20170007654A1 (en) | Use of veronia extract | |
US20140106009A1 (en) | Methods and compositions for maintaining and improving the health of skin | |
KR20200138142A (ko) | 구근추출물을 포함하는 피부 개선용 조성물 | |
WO2013114394A2 (en) | A polyherbal composition for skin care | |
KR100984010B1 (ko) | 탈모 방지 및 발모 촉진용 조성물 | |
KR102314813B1 (ko) | 피부-윤광 화장품 조성물 | |
KR102189330B1 (ko) | 구근추출물을 포함하는 피부 개선용 조성물 | |
KR101547758B1 (ko) | 탈모 예방 및 양모, 육모 촉진용 조성물 | |
JP2010184916A (ja) | 育毛剤 | |
KR101922637B1 (ko) | 마유 및 애기수영 추출물을 함유하는 피부 미백 및 주름 개선용 화장료 조성물 | |
JP3441722B2 (ja) | 化粧料 | |
JP2001335496A (ja) | ヘナの葉エキス、及びヘナ含有化粧料 | |
KR100521777B1 (ko) | 콜라겐 합성 촉진제를 포함하는 창상 치유용 피부 조성물 | |
WO2002051374A1 (fr) | Inhibiteurs de croissance capillaire et compositions contenant ces inhibiteurs | |
JP5717958B2 (ja) | セラミド産生促進剤、並びに該セラミド産生促進剤を用いた医薬品組成物、皮膚外用剤、化粧料組成物、及び化粧料 | |
CN115996702A (zh) | 用于增强皮肤的屏障功能的水飞蓟油 | |
JP3908245B2 (ja) | 養毛剤 | |
JP5855949B2 (ja) | ケラチン産生促進剤、染毛用剤及びマニキュア用剤 | |
JP2002284648A (ja) | 育毛剤組成物 | |
KR20090050856A (ko) | 승마 추출물의 분획추출물을 함유하는 미백화장료와 이의제조방법 | |
JP2003306415A (ja) | 化粧料 | |
JP6843537B2 (ja) | 抗皮膚老化剤及びそれを含有する外用化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130423 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130723 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130730 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130822 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130829 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130920 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130930 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131023 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140408 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140508 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5543329 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |